CCL5 and prostate carcinoma: The distinct functions of the two MAPKs may well be reproduced also in prostate cancer cells, as evidenced by our results with the inhibitors PD98059 and SB202190, thus suggesting that also in LNCaP cells p38 MAPK exerts a wider role than ERK1/2 on IL-6 and CCL5 transcription factors.